Novartis' Xolair successor hit by another PhIII axe, but food allergy study continues
Once thought to be a near shoe-in successor to Xolair, Novartis’ biologic ligelizumab hit another roadblock, with an additional Phase III scrapped, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
